ABOUT US

Eureka Therapeutics is a clinical-stage biotechnology company located in the Bay Area in California. Our mission is to disrupt solid tumor treatment by innovating safer and more effective T-cell therapies that overcome key limitations of current treatments.

 

We currently have two clinical trials: ARYA-2: ET140203 T Cells for pediatric subjects with AFP+ relapsed/refractory liver cancer such as hepatocellular carcinoma, hepatoblastoma and hepatocellular malignant neoplasm not-otherwise-specified.

 

Clinical trial site: Dana-Farber Cancer Institute in Boston, MA

 

US Clinical Trial # NCT04634357

 

ARYA-3: ECT204 T Cells for adult subjects with GPC3+ hepatocellular carcinoma and has failed at least two different anti-HCC systemic agents.

 

Clinical trial sites: Kansas University Medical Center in Kansas City, KS and City of Hope Medical Center in Los Angeles, CA

 

US Clinical Trial # NCT04864054

 

We are committed to collaborating with healthcare providers like you who share our passion for advancing cancer care. For more information about Eureka Therapeutics, or to refer a patient, please visit www.eurekatherapeutics.com.